Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   16/05/2024
1,140 USD (-3,39%)
(-3,39%)   16/05/2024

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET

CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.

Akebia will host a conference call on Thursday, May 9, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Registration Link and you will be provided with dial in details. To avoid delays, we encourage dialing into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-first-quarter-2024-financial-results-and-discuss-recent-business-highlights-302134491.html

SOURCE Akebia Therapeutics, Inc.

Mijn selecties